Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
Gut
    April 2021
  1. PHAM LV, Pedersen MS, Fahnoe U, Fernandez-Antunez C, et al
    HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Gut. 2021 Apr 8. pii: gutjnl-2020-323585. doi: 10.1136/gutjnl-2020-323585.
    >> Share

    January 2021
  2. BUKH J
    Vaccines against hepatitis C: a travel into neutralisation space.
    Gut. 2021 Jan 25. pii: gutjnl-2020-323377. doi: 10.1136/gutjnl-2020-323377.
    >> Share

  3. LIU CH, Chen CY, Su WW, Tseng KC, et al
    Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Gut. 2021 Jan 6. pii: gutjnl-2020-323569. doi: 10.1136/gutjnl-2020-323569.
    >> Share

    December 2020
  4. BANKWITZ D, Bahai A, Labuhn M, Doepke M, et al
    Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Gut. 2020 Dec 15. pii: gutjnl-2020-321190. doi: 10.1136/gutjnl-2020-321190.
    >> Share

  5. YU ML, Huang CF, Wei YJ, Lin WY, et al
    Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut. 2020 Dec 10. pii: gutjnl-2020-323277. doi: 10.1136/gutjnl-2020-323277.
    >> Share

    October 2020
  6. CASTRY M, Cousien A, Supervie V, Velter A, et al
    Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
    Gut. 2020 Oct 27. pii: gutjnl-2020-321744. doi: 10.1136/gutjnl-2020-321744.
    >> Share

    June 2020
  7. ZOLDAN K, Hofmann M
    B protected: from vertical HCV transmission?
    Gut. 2020 Jun 30. pii: gutjnl-2020-321364. doi: 10.1136/gutjnl-2020-321364.
    >> Share

    April 2020
  8. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.
    >> Share

  9. LUTCKII A, Strunz B, Zhirkov A, Filipovich O, et al
    Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus.
    Gut. 2020 Apr 27. pii: gutjnl-2019-320269. doi: 10.1136/gutjnl-2019-320269.
    >> Share

    March 2020
  10. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    >> Share

  11. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    >> Share

  12. YOUNOSSI ZM, Stepanova M, Younossi Y, Golabi P, et al
    Epidemiology of chronic liver diseases in the USA in the past three decades.
    Gut. 2020;69:564-568.
    >> Share

    February 2020
  13. CARPENTIER A, Sheldon J, Vondran FWR, Brown RJ, et al
    Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319354. doi: 10.1136/gutjnl-2019-319354.
    >> Share

    May 2019
  14. HERZOG K, Bandiera S, Pernot S, Fauvelle C, et al
    Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.
    Gut. 2019 May 10. pii: gutjnl-2018-317423. doi: 10.1136/gutjnl-2018-317423.
    >> Share

    September 2018
  15. LLIBRE A, Shimakawa Y, Duffy D
    Potential utility of the Genedrive point-of-care test for HCV RNA detection.
    Gut. 2018 Sep 22. pii: gutjnl-2018-317218. doi: 10.1136/gutjnl-2018-317218.
    >> Share

    June 2018
  16. LEMOINE M, Tillmann HL
    What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? 'Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus'.
    Gut. 2018 Jun 29. pii: gutjnl-2018-316438. doi: 10.1136/gutjnl-2018-316438.
    >> Share

  17. NEGRO F
    Expanded benefits of curing the extrahepatic manifestations of HCV infection.
    Gut. 2018 Jun 5. pii: gutjnl-2018-316578. doi: 10.1136/gutjnl-2018-316578.
    >> Share

    April 2018
  18. CACOUB P, Desbois AC, Comarmond C, Saadoun D, et al
    Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Gut. 2018 Apr 27. pii: gutjnl-2018-316234. doi: 10.1136/gutjnl-2018-316234.
    >> Share

  19. SHIHA G, Esmat G, Hassany M, Soliman R, et al
    Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Gut. 2018 Apr 17. pii: gutjnl-2017-315906. doi: 10.1136/gutjnl-2017-315906.
    >> Share

  20. LLIBRE A, Shimakawa Y, Mottez E, Ainsworth S, et al
    Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.
    Gut. 2018 Apr 3. pii: gutjnl-2017-315783. doi: 10.1136/gutjnl-2017-315783.
    >> Share

    March 2018
  21. SAMSON A, Bentham MJ, Scott K, Nuovo G, et al
    Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
    Gut. 2018;67:562-573.
    >> Share

    January 2018
  22. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.
    >> Share

    November 2017
  23. WANG X, Yan Y, Gan T, Yang X, et al
    A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey.
    Gut. 2017 Nov 27. pii: gutjnl-2017-314870. doi: 10.1136/gutjnl-2017-314870.
    >> Share

    July 2017
  24. PETTA S, Craxi A
    Can we prevent and modify cardiometabolic disorders by controlling HCV infection?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314505. doi: 10.1136/gutjnl-2017-314505.
    >> Share

    June 2017
  25. LEVANDER S, Holmstrom F, Frelin L, Ahlen G, et al
    Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
    Gut. 2017 Jun 23. pii: gutjnl-2016-313579. doi: 10.1136/gutjnl-2016-313579.
    >> Share

  26. MAHALE P, Engels EA, Li R, Torres HA, et al
    The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Gut. 2017 Jun 20. pii: gutjnl-2017-313983. doi: 10.1136/gutjnl-2017-313983.
    >> Share

  27. SUN HY, Cheng PN, Tseng CY, Tsai WJ, et al
    Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832.
    >> Share

  28. ARRIAZU E, Ge X, Leung TM, Magdaleno F, et al
    Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.
    Gut. 2017;66:1123-1137.
    >> Share

    March 2017
  29. COLPITTS CC, Tawar RG, Mailly L, Thumann C, et al
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.
    >> Share

  30. LAURAIN A, Kramer L, Sultanik P, Vallet-Pichard A, et al
    Mortality associated with the treatment of HCV with direct-acting antivirals.
    Gut. 2017 Mar 23. pii: gutjnl-2017-313869. doi: 10.1136/gutjnl-2017-313869.
    >> Share

    February 2017
  31. VAN RENNE N, Roca Suarez AA, Duong FH, Gondeau C, et al
    miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.
    >> Share

    January 2017
  32. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    >> Share

  33. BUDKOWSKA A
    Intriguing structure of the HCV particle.
    Gut. 2017 Jan 5. pii: gutjnl-2016-313184. doi: 10.1136/gutjnl-2016-313184.
    >> Share

    December 2016

  34. Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016;65:2060.
    >> Share

    November 2016
  35. ROINGEARD P, Dreneau J, Meunier JC
    Unravelling the multiple roles of apolipoprotein E in the hepatitis C virus life cycle.
    Gut. 2016 Nov 3. pii: gutjnl-2016-312774. doi: 10.1136/gutjnl-2016-312774.
    >> Share

    October 2016
  36. YOKOKAWA H, Higashino A, Suzuki S, Moriyama M, et al
    Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.
    Gut. 2016 Oct 26. pii: gutjnl-2016-312208. doi: 10.1136/gutjnl-2016-312208.
    >> Share

  37. PIVER E, Boyer A, Gaillard J, Bull A, et al
    Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture.
    Gut. 2016 Oct 11. pii: gutjnl-2016-311726. doi: 10.1136/gutjnl-2016-311726.
    >> Share

    September 2016
  38. CROUCHET E, Lefevre M, Verrier ER, Oudot MA, et al
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. 2016 Sep 8. pii: gutjnl-2015-311289. doi: 10.1136/gutjnl-2015-311289.
    >> Share

    June 2016
  39. GOUTTENOIRE J, Szkolnicka D, Moradpour D
    Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing.
    Gut. 2016 Jun 22. pii: gutjnl-2016-312040. doi: 10.1136/gutjnl-2016-312040.
    >> Share

    February 2016
  40. JAMIL KM, Hydes TJ, Cheent KS, Cassidy SA, et al
    STAT4-associated natural killer cell tolerance following liver transplantation.
    Gut. 2016 Feb 17. pii: gutjnl-2015-309395. doi: 10.1136/gutjnl-2015-309395.
    >> Share

    October 2015
  41. NAHON P, Lescat M, Layese R, Bourcier V, et al
    Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
    Gut. 2015 Oct 28. pii: gutjnl-2015-310275. doi: 10.1136/gutjnl-2015-310275.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016